Survey: Regulation hampers sustainability efforts

Validation and regulatory concerns top a list of obstacles that manufacturers face in adopting sustainability practices. Time constraints and a lack of in-house expertise are additional factors, according to a PharmaManufacturing.com survey. Article

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.